GPR119
Glucose-dependent insulinotropic receptor
As of the edition of 20 October 2026, GPR119 (glucose-dependent insulinotropic receptor, UniProt Q8TDV5) has 5 drugs tested at it and 6 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q8TDV5
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 10
- Disease areas
- Nutrition and metabolism; Hormones; Digestive system; Immune system
- Registered trials of its drugs
- 15
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 3 |
| Status not established | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| GSK-1292263 | Went quiet | Phase 2 | none listed |
| ADP-597 | Went quiet | Phase 1 | none listed |
| DA-1241 | Active | Phase 2 | none listed |
| MBX-2982 | Status not established | Phase 2 | none listed |
| PSN821 | Went quiet | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Johnson & Johnson | Route A |
| GSK | Route A |
| Prosidion | Route A |
The other 3 companies at GPR119
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at GPR119, ranked, with the facts behind eachRequest access. Nothing is shown until you do.